Español 
English
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región.
Artículos Relacionados
-
UDIBI
The dialyzable leukocyte extract TransferonTM inhibits tumor growth and brain metastasis in a murine model of prostate cancer. VER...
-
UDIBI
Quality attributes of partially hydrolyzed collagen in a liquid formulation used for skin care. VER MÁS
-
UDIBI
Fecha de publicación: Enero 2019Valproic acid promotes a decrease in mycobacterial survival by enhancing nitric oxide production in macrophages...
-
UDIBI
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. VER MÁS
-
UDIBI
Fecha de publicación: 8 noviembre 22 Altered neutrophil-to-lymphocyte ratio in sepsis secondary to canine parvoviral enteritis treated with and...
-
UDIBI
Mycobacterium tuberculosis Catalase Inhibits the Formation of Mast Cell Extracellular Traps. VER MÁS
-
UDIBI
Taking advantage of a high-throughput flow cytometer for the implementation of an ADCC assay for regulatory compliance. VER MÁS
-
UDIBI
Colloids and Surfaces A: Physicochemical and Engineering Aspects. Structural and physicochemical characteristics of one-step PAMAM dendrimeric nanoparticles. VER MÁS
